Pfizer to present more than 40 abstracts at ASCO annual meeting

Pfizer Inc. announced this week that it will have its largest number of abstracts presented at the American Society of Clinical Oncology (ASCO). 

The 52nd annual meeting will feature more than 40 Pfizer abstracts, including eight oral presentations and five poster discussions.

“Our significant presence at ASCO underscores our long-term commitment to oncology, cutting-edge science and the strength of collaborations to help bring forward potential new medicines that address the serious and complex needs of people battling cancer,” Pfizer Oncology Global President and General Manager Liz Barrett said. “We look forward to sharing our findings with the entire oncology community with the hope that our collective efforts will continue to advance innovative approaches and redefine life with cancer.”

Data on IBRANCE (palbociclib), XALKORI (crizotinib) and avelumab are among the highlights of the Pfizer presentations. Also on the agenda is the oral presentation on utomilumab, a 4-1BB agonist, used in combination with pembrolizumab, a PD-1 inhibitor, in the treatment of advanced solid tumors.

“Immunotherapy is revolutionizing the treatment of cancer, and Pfizer is advancing a diverse immuno-oncology pipeline with promise for patients with numerous types of cancer,” Pfizer Oncology VP and Head of Early Development, Translational and Immuno-Oncology Chris Boshoff said.